Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy

Urologia Internationalis

Volumn 80, Issue 4, 2008, Pages 451-453

  Di Silverio, Franco ^a   Sciarra, Alessandro ^a,b   Parente, Ulderico ^a   Andrea, Alfarone ^a   Von Heland, Magnus ^a   Panebianco, Valeria ^a   Passariello, Roberto ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NONE   (Italy)

Author keywords

Renal cancer; Sunitinib; Thrombus

Indexed keywords

SORAFENIB;

ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INVASION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG EFFECT; DRUG EFFICACY; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; INFERIOR CAVA VEIN OBSTRUCTION; KIDNEY CARCINOMA; KIDNEY VEIN THROMBOSIS; MALE; NEPHRECTOMY; PRIORITY JOURNAL; SYMPTOM; TREATMENT OUTCOME; TUMOR NECROSIS;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; FOLLOW-UP STUDIES; HUMANS; KIDNEY NEOPLASMS; MALE; NEOADJUVANT THERAPY; NEOPLASM CIRCULATING CELLS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEPHRECTOMY; PYRIDINES; RISK ASSESSMENT; TREATMENT OUTCOME; VENA CAVA, INFERIOR;

EID: 46249087574     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000132708     Document Type: Article

References (5)

1. Ferrara N: Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004;9:2-10.
2. Sosman JA, Puzanov I, Atkins MB: Opportunities and obstacles to combination targeted therapy in renal cell carcinoma. Clin Cancer Res 2007;13:764-769.
3. Karakiewicz PI, Suardi N, Jeldres C, Audet P, Ghosn P, Patard JJ, Perrotte P: Neoadjuvant sutent induction therapy may effectively down-stage renal cell carcinoma atrial thrombi. Eur Urol 2008;53:845-848.
4. Strimberg D, Clark JW: Safety, pharmacokinetics and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist 2007;12:426-437.
5. Escudier B, Szczylik C, Eisen T: Randomized phase III trial of the multikinase inhibitor sorafenib in patients with advanced renal cell carcinoma. Eur J Cancer Suppl 2005;3:226.